• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K/A filed

    1/28/21 5:30:27 PM ET
    $CVLB
    Get the next $CVLB alert in real time by email
    8-K/A 1 form8-ka.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K/A

    (Amendment No. 1)

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 22, 2021

     

    CONVERSION LABS, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-39785   76-0238453

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    800 Third Avenue, Suite 2800

    New York, NY 10022

    (Address of principal executive offices, including zip code)

     

    (866) 351-5907

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    [  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    [  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    [  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    [  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Title of each class   Trading Symbol(s)  

    Name of each exchange on which

    registered

    Common Stock   CVLB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company [  ]

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

     

     

     

     
     

     

    Explanatory Note

     

    This Current Report on Form 8-K/A is being filed to (i) clarify that management of LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LSS”), a majority-owned subsidiary of the Company entered into option agreements with members of LSS management that would allow them to re-purchase 12,400 membership interest purchase units of LSS, subject to vesting of such options in connection with achieving certain performance milestones as described herein (ii) to include additional exhibits to our original Current Report on Form 8-K filed with the Securities and Exchange Commission on January 26, 2021 and (iii) include the press release in connection with the transaction. All of the original exhibits filed with the initial Current Report on form 8-K filed on January 26, 2021 are being refiled with on this Form 8K/A for ease of reference and to reflect the foregoing.

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    LegalSimpli Software Restructuring Transaction

     

    Effective January 22, 2021, Conversion Labs, Inc., a Delaware corporation (the “Company”), consummated a transaction to restructure the ownership of LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LSS”), a majority-owned subsidiary of the Company (the “LSS Restructuring”). To affect the LSS Restructuring the Company’s wholly-owned subsidiary Conversion Labs PR LLC, a Puerto Rico limited liability company (“CVLB PR”) entered into a series of agreements as further described below.

     

    Membership Interest Exchange Agreement

     

    Effective January 22, 2021 (the “Effective Date”), in furtherance of the LSS Restructuring, CVLB PR entered into a Membership Interest Exchange Agreement with LSS, (the “Exchange Agreement”), pursuant to which, CVLB PR exchanged that certain a promissory note, dated May 8, 2019 with an outstanding balance of $375,823.17 (the “CVLBPR Note”), issued by LSS in favor of CVLB PR, for 37,531 newly issued membership interests of LSS (the “Exchange”). Upon consummation of the Exchange the CVLBPR Note was extinguished.

     

    Membership Interest Purchase Agreements

     

    On the Effective Date, in furtherance of the LSS Restructuring, CVLB PR entered into a Membership Interest Purchase Agreement with LSS, (the “CVLB PR MIPA”), pursuant to which CVLB PR purchased 12,000 membership interests of LSS for an aggregate purchase price of $300,000. The CVLB PR MIPA provides that the transaction may be completed in three (3) tranches with a purchase price of $100,000 per tranche to be made at the sole discretion of CVLB PR. Payment for the first tranche of $100,000 was made upon execution of the CVLB PR MIPA. Payments for the second and third tranches are due on the 60-day anniversary and the 120-day anniversary of the Effective Date.

     

    Concurrently, in furtherance of the LSS Restructuring, CVLB PR entered into two Membership Interest Purchase Agreements (the “Founding Members MIPAs”) with two founding members of LSS (the “Founding Members”) whereby CVLB PR purchased from the Founding Members an aggregate of 2,183 membership interests of LSS for an aggregate purchase price of $225,000.

     

    Following the consummation of the LSS Restructuring, CVLB PR will increase its ownership of LSS from 51% to approximately 85.58% on a fully diluted basis. LSS entered into an amendment to its operating agreement (the “LSS Operating Agreement Amendment”) to reflect the foregoing.

     

     
     

     

    LSS Option Agreements

     

    Concurrently, CVLB PR entered into option agreements with Sean Fitzpatrick (the “Fitzpatrick Option Agreement”) and Varun Pathak (the “Pathak Option Agreement” together with Fitzpatrick Option Agreement the “Option Agreements”), pursuant to which CVLB PR granted options to purchase membership interest units of LSS. The Fitzpatrick Option Agreement grants Sean Fitzpatrick the option to purchase 10,300 membership interest units of LSS for an exercise price of $1.00 per membership interest unit.

     

    The Fitzpatrick Options vest in accordance with the following (i) 3,434 membership interests upon LSS achieving $2,500,000 of gross sales in any fiscal quarter (ii) 3,434 membership interests upon LSS achieving $4,000,000 of gross sales in any fiscal quarter and (iii) 3,434 membership interests upon LSS achieving $8,000,000 of gross sales with a ten percent (10%) net profit margin in any fiscal quarter.

     

    The Pathak Options shall vest in accordance with the following (i) 700 membership interests upon LSS achieving $2,500,000 of gross sales in any fiscal quarter (ii) 700 membership interests upon LSS achieving $,4,000,000 of gross sales in any fiscal quarter and (iii) 700 membership interests upon LSS achieving $8,000,000 of gross sales with a ten percent (10%) net profit margin in any fiscal quarter.

     

    Upon vesting, the Fitzpatrick Options and the Pathak Options provide for the potential re-purchase of up to an additional 13.25%% of LSS by Fitzpatrick and Pathak in the aggregate with CVLB PR ownership ratably reduced to approximately 72.98%.

     

    The foregoing provides only brief descriptions of the material terms of the LSS Restructuring, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the full text of the forms of the CVLB PR Exchange Agreement, the CVLB PR MIPA, the Founding Members MIPA, the LSS Operating Agreement Amendment, the Fitzpatrick Option Agreement and Pathak Option Agreement filed as exhibits to this Current Report on Form 8-K, and are incorporated herein by reference.

     

    Item 2.03 Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The disclosure provided under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 8.01 Other Events.

     

    On January 28, 2021, the Company issued a press release announcing the Appointment. A copy of the press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference.

      

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit No.   Description
    10.1   Form of CVLB PR Exchange Agreement (Incorporated herein by reference to Exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed on January 26, 2021)
    10.2   Form of CVLB PR MIPA (Incorporated herein by reference to Exhibit 10.2 filed with the Company’s Current Report on Form 8-K filed on January 26, 2021)
    10.3   Form of Founding Members MIPA (Incorporated herein by reference to Exhibit 10.3 filed with the Company’s Current Report on Form 8-K filed on January 26, 2021)
    10.4*   Amendment to LSS Operating Agreement
    10.5*   Fitzpatrick Option Agreement
    10.6*   Pathak Option Agreement
    99.1*   Press Release dated January 28, 2021

     

    * filed herewith

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CONVERSION LABS INC..
         
    Date: January 28, 2021 By: /s/ Justin Schreiber
      Name: Justin Schreiber
      Title: Chief Executive Officer

     

     

     

     

     

    Get the next $CVLB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVLB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Conversion Labs with a new price target

      BTIG Research reiterated coverage of Conversion Labs with a rating of Buy and set a new price target of $40.00 from $15.00 previously

      2/18/21 9:19:07 AM ET
      $CVLB
    • B. Riley FBR initiated coverage on Conversion Labs with a new price target

      B. Riley FBR initiated coverage of Conversion Labs with a rating of Buy and set a new price target of $35.00

      2/5/21 6:59:45 AM ET
      $CVLB

    $CVLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: David Happy Walters was granted 1,200,000 units of Common Stock, increasing ownership by 149% to 1,336,300 units

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/26/21 10:04:47 AM ET
      $CVLB
    • SEC Form 4: Harold Eric Yecies bought $100,400 worth of Common Stock (5,000 units at $20.08)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 7:16:47 PM ET
      $CVLB
    • SEC Form 4: Michael Brad Roberts bought $102,500 worth of Common Stock (5,000 units at $20.50)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 6:13:10 PM ET
      $CVLB

    $CVLB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD

      NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock’s new CUSIP number will be 53216B 104. “Our new name reflects our evolution from a healthcare-focused performance marketing business into a leading provider of personalized, direct to patient telehealth services,” stated Justin Schreiber, LifeMD’s co-founder and CEO. “Our vision is to radically change healthcare by making access to the best physicians and prescription medications easily accessible, convenient, and aff

      2/22/21 3:30:00 AM ET
      $CVLB
    • Conversion Labs to Become Life MD™ with Launch of New Concierge Telehealth Services

      NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare. “We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more conven

      2/12/21 8:30:00 AM ET
      $CVLB
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB

    $CVLB
    Leadership Updates

    Live Leadership Updates

    See more
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

      NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals. Dr. Puopolo brings to Conversion Labs more than 20 years of execut

      1/11/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

      NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value. Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and custo

      1/5/21 10:15:00 AM ET
      $CVLB

    $CVLB
    SEC Filings

    See more

    $CVLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 8-K filed

      8-K - LifeMD, Inc. (0000948320) (Filer)

      2/26/21 5:00:48 PM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/22/21 7:30:16 AM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/12/21 8:30:10 AM ET
      $CVLB
    • SEC Form SC 13D filed by Conversion Labs, Inc.

      SC 13D - LifeMD, Inc. (0000948320) (Subject)

      3/19/21 4:15:12 PM ET
      $CVLB